Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $19.40 Average PT from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus rating of “Hold” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.40.

Several brokerages recently issued reports on TBPH. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. TD Cowen lifted their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 27th. HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their target price for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. Finally, JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. This represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the transaction, the insider directly owned 9,174,453 shares in the company, valued at $155,965,701. This trade represents a 0.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 350,011 shares of company stock valued at $6,008,309. Company insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Quarry LP bought a new position in shares of Theravance Biopharma in the third quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $16.93 on Thursday. The stock’s 50-day simple moving average is $16.62 and its two-hundred day simple moving average is $17.19. The stock has a market capitalization of $872.74 million, a price-to-earnings ratio of 7.70 and a beta of 0.17. Theravance Biopharma has a 52-week low of $10.82 and a 52-week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, equities analysts forecast that Theravance Biopharma will post 1.54 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.